Sumitomo Pharma Co., Ltd.
4506
Classement en actions
#3141
Sumitomo Pharma Co., Ltd. is a global company involved in the creation,... Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
Prix de l'action
$12.86
Capitalisation boursière
$5.77B
Changement (1 jour)
4.48%
Changement (1 an)
15.98%
Pays
JP
Échange Sumitomo Pharma Co., Ltd. (4506)
Catégorie
Healthcare
Bénéfices pour Sumitomo Pharma Co., Ltd. (4506)
Bénéfices en Jun 2026 TTM : $696.20M
Selon les derniers rapports financiers de Sumitomo Pharma Co., Ltd., les bénéfices actuels de l'entreprise sont de $696.20M. En 2024, l'entreprise a réalisé un bénéfice de $-2.13B, une diminution par rapport à celui de 2023 qui était de $-360.91M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Sumitomo Pharma Co., Ltd. de 2005 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $696.20M | 492.57% |
| 2025 | $117.49M | -105.50% |
| 2024 | $-2.13B | 491.50% |
| 2023 | $-360.91M | -152.97% |
| 2022 | $681.35M | -3.06% |
| 2021 | $702.89M | -9.98% |
| 2020 | $780.81M | 33.24% |
| 2019 | $586.00M | -26.64% |
| 2018 | $798.75M | 88.42% |
| 2017 | $423.92M | 20.57% |
| 2016 | $351.60M | 24.93% |
| 2015 | $281.43M | -16.37% |
| 2014 | $336.52M | 74.64% |
| 2013 | $192.69M | -2.09% |
| 2012 | $196.80M | -34.88% |
| 2011 | $302.19M | -10.14% |
| 2010 | $336.28M | 2.87% |
| 2009 | $326.90M | -21.37% |
| 2008 | $415.75M | 27.67% |
| 2007 | $325.63M | 49.13% |
| 2006 | $218.36M | 100.02% |
| 2005 | $109.17M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 153.46% |
IN
|
